Activation of STING in the pancreatic tumor microenvironment: a novel therapeutic opportunity
Pancreatic ductal adenocarcinoma (PDAC) is a cancer of poor prognosis that presents with
a dense desmoplastic stroma that contributes to therapeutic failure. PDAC patients are …
a dense desmoplastic stroma that contributes to therapeutic failure. PDAC patients are …
The Current Landscape of Clinical Trials for Immunotherapy in Pancreatic Cancer: A State-of-the-Art Review
Background Pancreatic cancer remains a lethal malignancy with a 5-year survival rate
below 6% and about 500,000 deaths annually worldwide. Pancreatic adenocarcinoma, the …
below 6% and about 500,000 deaths annually worldwide. Pancreatic adenocarcinoma, the …
Machine-learning-based bibliometric analysis of pancreatic cancer research over the past 25 years
Machine learning and semantic analysis are computer-based methods to evaluate complex
relationships and predict future perspectives. We used these technologies to define recent …
relationships and predict future perspectives. We used these technologies to define recent …
Next generation of cancer drug repurposing: therapeutic combination of aspirin and oseltamivir phosphate potentiates gemcitabine to disable key survival pathways …
Simple Summary Drug repurposing in combination with clinical standard chemotherapeutics
opens a novel and promising clinical treatment approach for patients with pancreatic cancer …
opens a novel and promising clinical treatment approach for patients with pancreatic cancer …
A novel anti-galectin-9 immunotherapy limits the early progression of pancreatic neoplastic lesions in transgenic mice
A Quilbe, R Mustapha, B Duchêne, A Kumar… - Frontiers in …, 2023 - frontiersin.org
Background Pancreatic adenocarcinoma (PDAC) is a devastating disease with an urgent
need for therapeutic innovation. Immune checkpoint inhibition has shown promise in a …
need for therapeutic innovation. Immune checkpoint inhibition has shown promise in a …
Momordicae Semen inhibits migration and induces apoptotic cell death by regulating c-Myc and CNOT2 in human pancreatic cancer cells
W Jee, HM Ko, DI Park, YR Park, SM Park, H Kim… - Scientific Reports, 2023 - nature.com
Pancreatic cancer (PC) is less common than other cancers; however, it has a poor
prognosis. Therefore, studying novel target signaling and anticancer agents is necessary …
prognosis. Therefore, studying novel target signaling and anticancer agents is necessary …
PET imaging and treatment of pancreatic cancer peritoneal carcinomatosis after subcutaneous intratumoral administration of a novel oncolytic virus, CF33-hNIS …
Z Zhang, A Yang, S Chaurasiya, AK Park, SI Kim… - Molecular Therapy …, 2022 - cell.com
Peritoneal carcinomatosis of gastrointestinal malignancies remains fatal. CF33-hNIS-
antiPDL1, a chimeric orthopoxvirus expressing the human sodium iodide symporter (hNIS) …
antiPDL1, a chimeric orthopoxvirus expressing the human sodium iodide symporter (hNIS) …
[HTML][HTML] TGFB2 mRNA Levels Prognostically Interact with Interferon-Alpha Receptor Activation of IRF9 and IFI27, and an Immune Checkpoint LGALS9 to Impact …
S Qazi, V Trieu - International Journal of Molecular Sciences, 2024 - mdpi.com
The treatment of pancreatic ductal adenocarcinoma (PDAC) is an unmet challenge, with the
median overall survival rate remaining less than a year, even with the use of FOLFIRINOX …
median overall survival rate remaining less than a year, even with the use of FOLFIRINOX …
Women patients with small‐cell lung cancer using immunotherapy in a real‐world cohort achieved long‐term survival
Y He, L Kong, X Ji, M Zhuo, T An, B Jia, Y Chi… - Thoracic …, 2024 - Wiley Online Library
Background Usage of immune checkpoint inhibitors (ICIs) has prolonged the overall survival
(OS) of patients with extensive‐stage small‐cell lung cancer (ES‐SCLC). In clinical trials …
(OS) of patients with extensive‐stage small‐cell lung cancer (ES‐SCLC). In clinical trials …
[HTML][HTML] Systematic review of the predictors of health service use in pancreatic cancer
Introduction: Pancreatic cancer (PC) has a dismal prognosis, with identified disparities in
survival outcomes based on demographic characteristics. These disparities may be …
survival outcomes based on demographic characteristics. These disparities may be …